Please provide your email address to receive an email when new articles are posted on . The phase 2 study of ALTO-203 will involve about 60 adults with MDD and evidence of anhedonia. ALTO-203 has ...
Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.
Another of Alto Neurosciences’ machine learning-derived, biomarker-based depression therapies has improved symptoms, boosting the case for the biotech’s precision psychiatry approach. ALTO-300 was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results